key: cord-0291393-tt3zpebr
authors: Boschi, Céline; Colson, Philippe; Bancod, Audrey; Moal, Valérie; Scola, Bernard La
title: Omicron variant escapes therapeutic mAbs contrary to eight prior main VOC
date: 2022-01-03
journal: bioRxiv
DOI: 10.1101/2022.01.03.474769
sha: 5138f962286025f0840f7f4193918dbd1454e240
doc_id: 291393
cord_uid: tt3zpebr

Monocolonal antibodies (mAbs) are currently used for active immunization of COVID-19 in immunocompromised patients. We herein show that in spite there are variations in susceptibility to available mAbs that are authorized for clinical use in France tested on the original B.1.1 virus and 9 variants of concern or of interest, the cocktail casirivimab/imdevimab (REGN-CoV-2) showed a major synergistic effect. However, none of the four mAbs either alone or in combination neutralized the new Omicron variant. Our data strongly warrant a reinforcement of protective measures against infection for immunocompromised patients.

Monocolonal antibodies (mAbs) are currently used for active immunization of 11 COVID-19 in immunocompromised patients. We herein show that in spite there are variations 12 in susceptibility to available mAbs that are authorized for clinical use in France tested on the 13 original B.1.1 virus and 9 variants of concern or of interest, the cocktail Monocolonal antibodies (mAbs) are currently used for active immunization of 20 COVID-19 in immunocompromised patients that do not respond to a complete vaccine 21 schedule. As described previously 1 , we tested the neutralizing activity of four mAbs that are Bamlavinimab and etesevimab were diluated each in a 1:5 serial dilutions (from 3500 µg/mL 117 to 0.0089 µg/mL). For the combination of the two mAbs, we tested the mixture in the highest 118 concentration for each mAbs alone with 2 times more etesevimab than bamlavinimab.

Casirivimab and imdevimab were diluated each in a 1:5 serial dilutions (from 12 000 µg/mL 120 to 0,00614 µg/mL). For the combination of these two mAbs, we tested the mixture in the 121 highest concentration for each mAbs alone in the same proportion.

Each dilution of mAbs was mixed volume by volume with each viral strains with standardized 124 inoculum at 25 Ct as previously described 4 . The mixture of viral suspension and mAbs was 125 incubated 1h at 37 ° C under 5% CO 2 . Then, 100μl of medium in the 96-well plates was 126 removed and 100μL of the mixture for each dilution was added in quadruplate on the Vero E6 127 cells. Five days post-viral infection, cytopathic effect was determined with the inverted 128 optical microscope to determine the neutralization titer to obtain 50% of neutralization. Each 129 mAbs and combination of mAbs were tested three times against the 10 SARS-CoV-2 strains, 130 except for omicron variant that was tested four times.

Viral RNA load as determined by cell culture as a management tool 133 for discharge of SARS-CoV-2 patients from infectious disease wards

Correlation Between 3790 Quantitative Polymerase Chain Reaction-136

Positives Samples and Positive Cell Cultures, Including 1941 Severe Acute Respiratory 137

Syndrome Coronavirus 2 Isolates

Spreading of a new SARS-CoV-2 N501Y spike variant in a new 140 lineage

High Individual Heterogeneity of Neutralizing Activities against the 143

Original Strain and Nine Different Variants of SARS-CoV-2

Supplementary figure S1: 146 Neutralization curves in Vero E6 cells for each strains tested with each mAb : A, C, E, G, I,